Analysts expect Endo International plc (NASDAQ:ENDP) (TSE:ENL) to post $687.12 million in sales for the current fiscal quarter, according to Zacks. Eight analysts have provided estimates for Endo International’s earnings, with the highest sales estimate coming in at $704.20 million and the lowest estimate coming in at $663.20 million. Endo International reported sales of $1.04 billion in the same quarter last year, which would indicate a negative year over year growth rate of 33.9%. The business is expected to announce its next earnings results before the market opens on Tuesday, May 8th.
On average, analysts expect that Endo International will report full year sales of $2.74 billion for the current fiscal year, with estimates ranging from $2.66 billion to $2.79 billion. For the next year, analysts anticipate that the company will report sales of $2.75 billion per share, with estimates ranging from $2.51 billion to $2.93 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Endo International.
Endo International (NASDAQ:ENDP) (TSE:ENL) last issued its quarterly earnings data on Tuesday, February 27th. The company reported $0.77 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.15. The business had revenue of $768.64 million for the quarter, compared to analyst estimates of $762.29 million. Endo International had a positive return on equity of 81.03% and a negative net margin of 58.68%. Endo International’s quarterly revenue was down 38.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.77 EPS.
A number of equities research analysts have commented on ENDP shares. Vetr upgraded Endo International from a “buy” rating to a “strong-buy” rating and set a $8.92 price target on the stock in a research report on Tuesday, December 26th. ValuEngine lowered Endo International from a “buy” rating to a “hold” rating in a research report on Sunday, December 31st. Leerink Swann started coverage on Endo International in a research report on Tuesday, January 2nd. They issued an “outperform” rating and a $12.00 price target on the stock. Mizuho reiterated a “buy” rating and issued a $12.00 price target (down previously from $14.00) on shares of Endo International in a research report on Wednesday, January 3rd. Finally, Cantor Fitzgerald set a $7.00 target price on Endo International and gave the company a “hold” rating in a research report on Thursday, January 11th. Four equities research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $9.40.
ENDP stock traded down $0.13 during midday trading on Monday, reaching $5.61. 1,696,709 shares of the stock were exchanged, compared to its average volume of 5,572,613. The firm has a market capitalization of $1,241.77, a P/E ratio of 1.44 and a beta of 0.38. Endo International has a 52 week low of $5.27 and a 52 week high of $14.15. The company has a quick ratio of 0.85, a current ratio of 1.02 and a debt-to-equity ratio of 17.00.
Several institutional investors have recently modified their holdings of the company. River & Mercantile Asset Management LLP raised its stake in shares of Endo International by 32.7% in the fourth quarter. River & Mercantile Asset Management LLP now owns 475,650 shares of the company’s stock worth $3,679,000 after purchasing an additional 117,110 shares during the last quarter. Alps Advisors Inc. increased its position in shares of Endo International by 22.9% during the fourth quarter. Alps Advisors Inc. now owns 307,839 shares of the company’s stock valued at $2,386,000 after acquiring an additional 57,328 shares during the last quarter. UBS Asset Management Americas Inc. increased its position in shares of Endo International by 4.4% during the fourth quarter. UBS Asset Management Americas Inc. now owns 221,992 shares of the company’s stock valued at $1,720,000 after acquiring an additional 9,438 shares during the last quarter. Quantitative Investment Management LLC purchased a new stake in shares of Endo International during the fourth quarter valued at approximately $1,569,000. Finally, Systematic Financial Management LP increased its position in shares of Endo International by 22.5% during the fourth quarter. Systematic Financial Management LP now owns 190,550 shares of the company’s stock valued at $1,477,000 after acquiring an additional 35,045 shares during the last quarter. 94.77% of the stock is owned by hedge funds and other institutional investors.
Endo International Company Profile
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.